Presented by: Lynette Schroeter-Tedesco and Jonathan Alvarez, Ajinomoto Althea
Presented Live: May 15, 2018
The Crystalomics® Department at Ajinomoto Althea CMO uses crystallized biotherapeutics to develop high concentration, low viscosity injectable drug formulations exceeding 200 mg/mL. The first step in our technology is to discover and develop crystallization conditions as rapidly as possible in order to meet short development timelines.
Crystallization of proteins, especially monoclonal antibodies (mAbs), is very challenging and typically employs extensive trial-and-error. Incorporating high-throughput dynamic light scattering (HT-DLS) into our pre-crystallization screening to characterize the protein in multiple buffers, we are able to significantly reduce the extent of crystallization trials. Analysis of the mAbs by multi-angle light scattering coupled to size-exclusion chromatography (SEC-MALS) as well as HT-DLS is critical to determining optimal crystallization conditions with minimal time and effort.